Drugs / LY4086940
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06945419 | Apr 2025 → Aug 2026 overdue | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4086940 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06945419 ↗ |
| Route | Oral | “Administered orally” NCT06945419 ↗ |